Advertisement

Topics

Latest "MBio Diagnostics, Inc." News Stories

20:35 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "MBio Diagnostics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about MBio Diagnostics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about MBio Diagnostics, Inc. for you to read. Along with our medical data and news we also list MBio Diagnostics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of MBio Diagnostics, Inc. Companies for you to search.

Showing "MBio Diagnostics" News Articles 1–25 of 2,400+

Wednesday 20th February 2019

Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

First-in-class antibody targeting B7-H4 Dual mechanism blocks a T cell checkpoint pathway and delivers potent antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that express B7-H4 B7-H4 is over-expressed on hard-to-treat solid tumors with low response to checkpoint inhibition ...


Veracyte Announces Participation in Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) today announced that members of its management team will be participating in two upcoming investor conferences. Executives from the company will be meeting with investors at the BTIG MedTech, Life Science & Diagnostic Tools Conference 2019 on Wednesday, February 27, 2019, in Snowbird, Utah. There will not be a webcasted ...

Melanoma Research Alliance Welcomes FDA Approval of Pembrolizumab in Adjuvant Setting

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food & Drug Administration (FDA) approval of Merck’s pembrolizumab (Keytruda®) in the adjuvant setting for melanoma patients with lymph node involvement following complete lymph node resection. Melanoma, the deadliest skin c...


SQI Diagnostics Announces Private Placement with Insider Participation

SQI Diagnostics (TSXV:SQD;OTCQB:SQIDF) has announced it will complete a non-brokered private placement of up to 31.25 million units of the company at $0.08 per unit for gross proceeds of up to $2.5 million. As quoted in the press release: Each Unit will consist of one common share and one common share purchase warrant. Each common … Continued The post SQI Diagnostics Announces Private Placem...

Colorado BioScience Association Connects Lawmakers to Patient-Focused Innovators at Capitol Event

New results highlight success of state-funded grant program for early-stage life science companies Colorado BioScience Association (CBSA) brings healthcare innovators to the state Capitol to highlight the impact Colorado’s life science companies and organizations make for patients. Leaders working on breakthrough medicines, medical devices, di...

Agilent Presents Thought Leader Award to Professor Diether Lambrechts

Belgian scientist recognized for his research in cancer genomics Agilent Technologies Inc. (NYSE: A) today announced that Professor Die

Reconfirming the Group A Strep Diagnostic Algorithm with Molecular Confirmation, New Webinar Hosted by Xtalks

While our understanding of Group A Strep has remained robust and unchanged, our methods of detection and testing have improved dramatically. Join this free webinar to learn about the latest in Group A Strep diagnostics using molecular confirmation techniques. TORONTO (PRWEB) February 20, 2019 Group A Streptococcus (Group A Strep) remains fairly unchanged and is well-understood by the scientific c...

$MBIO and Nationwide Children’s Hospital Enter into License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme $FBIO https://globenewswire.com/news-release/2019/02/20/1738379/0/en/Mustang-Bio-and-Nationwide-Children-s-Hospital-Enter-i

$MBIO and Nationwide Children’s Hospital Enter into License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme $FBIO https://globenewswire.com/news-release/2019/02/20/173837

Qiagen enters agreement with precision diagnostics company

The German company has received an exclusive license to use Ares Genetics s database and toolbox, to develop bioinformatics and assays for antimicrobial resistance research

Radiology Business Management Association and Ultrasound Access Coalition Highlight Impending Ultrasound Cuts

Ultrasound stakeholders lead delay in $112 million reduction in ultrasound services (PRWEB) February 20, 2019 Radiology Business Management Association (RBMA) and the Ultrasound Access Coalition (UAC) today highlighted the significant pending cuts to Medicare reimbursement for ultrasound ser-vices. UAC successfully prevented a $112 million reduction in ultrasound services, originally proposed to ...

Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy(r) Lung Cancer Trial in China

Cambridge, UK, and Shanghai, China, February 20 2019:  Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, today announced a collaboration to conduct a clinical trial into the early detection of lung cancer with support from the Li Ka Shing Foundation. Recognizing the escal...

Creative Diagnostics Announces Mycotoxins Analysis for Researchers

As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics has announced the launch of a series of new, innovative mycotoxins analysis products and services for customers globally. Conjugates, antibodies and test kits for all relevant mycotoxins now are supplied by Creative Diagnostics, such as Aflatoxin, Citrinin, DON (Vomitoxin), ...

Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China

Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, today announced a collaboration to conduct a clinical trial into the early detection of lung cancer with support from the Li Ka Shing Foundation. Recognizing the escalating incidence ...

GENSPEED Biotech: Novel Point-of-Care Testing Technology Enables Rapid Test for Medical Risk Classification

Austrian GENSPEED Biotech GmbH and Virogates A/S (Nasdaq First North Denmark: VIRO) have commenced a partnership to develop a rapid test for the risk classification of acute and chronic patients on site. The test targets to simultaneously analyze for C- Reactive Protein and suPAR from a finger prick in less than 10 minutes. Immediate results suppo...

Beijing GenomePrecision Raises $15 Million for Molecular Diagnostics

GenomePrecision Technology of Beijing completed a $15 million B round, led by Yizhuang Biomedical M&A Fund. A six-year-old company, GenomePrecision develops molecular diagnostic products including precision medicine tests. Its operations include R&D, manufacturing, distribution, registration and services. The company has developed multiple series of tests for leukemia, lymphoma, transplant...

Global MicroPump Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global MicroPump market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major products ...

Tuesday 19th February 2019

GenMark Diagnostics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences. GenMark’s management team will be participating in one-on-one meetings at the BTIG MedTech, Life Science & Diagnostic Tools...

Xerox’s Wolfson Joins Quest as Chief Information and Digital Officer

Quest Diagnostics (NYSE: DGX) has appointed Gabrielle Wolfson to serve as senior vice president and chief information and digital officer. Wolfson comes to Secaucus, NJ-based Quest from Xerox (NYSE: XRX), where she was chief information officer. Her experience includes serving as CIO for both Integra Life Sciences and Par Pharmaceutical. Quest provides an array of […]

Accelerate Diagnostics, Inc. (AXDX) CEO Lawrence Mehren on Q4 2018 Results - Earnings Call Transcript

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director

CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director. Dr. Schmidt will lead the laboratory’s precision medicine initiatives and work to educate the medical community about CIRCULOGENE’s molecular diagnostics capabilities and next-generation sequencing (N...

Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand, [18F]MK-6240

This week Institut de Radiofarmacia Aplicada de Barcelona, S.L. (IRAB), a leading producer of imaging biomarkers for use in clinical research, has signed an agreement that grants the company the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. This will facilitate clinical studies assess...

Mark Hozza Named Chief Commercial Officer at BioInformatics Inc.

BioInformatics Inc. appoints Mark Hozza as Chief Commercial Officer to lead the life science research and advisory firm's sales organization. ARLINGTON, Va. (PRWEB) February 19, 2019 BioInformatics Inc., part of Science and Medicine Group, today announced the appointment of Mark Hozza as Chief Commercial Officer of the life science research and advisory firm. As the leader of the sales organi...

Smarter Medicine: Using AI for Cancer Diagnostics

ArticleThe cancer diagnostic chain remains a fragile process susceptible to human error.Contributed Author: 

Head Position During Sleep Has Potential Implications for Neurodegenerative Disease

Could sleeping on your back increase your brain's risk of developing neurodegenerative disease? That possibility is revealed in a new study published in the Journal of Alzheimer's Disease. "We compared the in-home sleep patterns of patients with memory impairment resulting from neurodegenerative diseases to a large group of elderly wit...

Nexien BioPharma Announces Executive and Business Updates

Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB:NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced executive and business updates. Dr. Joseph F. Aceto, JD, Ph.D. has been app...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks